Multisite phosphorylation of nuclear interaction partner of ALK (NIPA) at G2/M involves cyclin B1/Cdk1

被引:24
作者
Bassermann, Florian
von Klitzing, Christine
Illert, Anna Lena
Muench, Silvia
Morris, Stephan W.
Pagano, Michele
Peschel, Christian
Duyster, Justus
机构
[1] Tech Univ Munich, Dept Internal Med 3, D-81675 Munich, Germany
[2] St Jude Childrens Hosp, Dept Pathol, Memphis, TN 38105 USA
[3] St Jude Childrens Hosp, Dept Hematol Oncol, Memphis, TN 38105 USA
[4] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA
[5] NYU, Sch Med, Inst Canc, New York, NY 10016 USA
关键词
D O I
10.1074/jbc.M610819200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Nuclear interaction partner of ALK (NIPA) is an F-box-containing protein that defines a nuclear skp1 cullin F-box (SCF)type ubiquitin E3 ligase (SCFNIPA) implicated in the regulation of mitotic entry. The SCFNIPA complex targets nuclear cyclin B1 for ubiquitination in interphase, whereas phosphorylation of NIPA in late G(2) phase and mitosis inactivates the complex to allow for accumulation of cyclin B1. Here, we identify the region of NIPA that mediates binding to its substrate cyclin B1. In addition to the recently described serine residue 354, we specify 2 new residues, Ser-359 and Ser-395, implicated in the phosphorylation process at G(2)/M within this region. Moreover, we found cyclin B1/Cdk1 to phosphorylate NIPA at Ser-395 in mitosis. Mutation of both Ser-359 and Ser-395 impaired effective inactivation of the SCFNIPA complex, resulting in reduced levels of mitotic cyclin B1. These data are compatible with a process of sequential NIPA phosphorylation where cyclin B1/Cdk1 amplifies phosphorylation of NIPA once an initial phosphorylation event has dissociated the SCFNIPA complex. Thus, cyclin B1/Cdk1 may contribute to the regulation of its own abundance in early mitosis.
引用
收藏
页码:15965 / 15972
页数:8
相关论文
共 36 条
  • [1] SKP1 connects cell cycle regulators to the ubiquitin proteolysis machinery through a novel motif, the F-box
    Bai, C
    Sen, P
    Hofmann, K
    Ma, L
    Goebl, M
    Harper, JW
    Elledge, SJ
    [J]. CELL, 1996, 86 (02) : 263 - 274
  • [2] Mitotic entry - A matter of oscillating destruction
    Bassermann, F
    Peschel, C
    Duyster, J
    [J]. CELL CYCLE, 2005, 4 (11) : 1515 - 1517
  • [3] NIPA defines an SCF-type mammalian E3 ligase that regulates mitotic entry
    Bassermann, F
    von Klitzing, C
    Münch, S
    Bai, RY
    Kawaguchi, H
    Morris, SW
    Peschel, C
    Duyster, J
    [J]. CELL, 2005, 122 (01) : 45 - 57
  • [4] Association of Bcr-Abl with the proto-oncogene Vav is implicated in activation of the Rac-1 pathway
    Bassermann, F
    Jahn, T
    Miething, C
    Seipel, P
    Bai, RY
    Coutinho, S
    Tybulewicz, VL
    Peschel, C
    Duyster, J
    [J]. JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (14) : 12437 - 12445
  • [5] Degradation of Cdc25A by β-TrCP during S phase and in response to DNA damage
    Busino, L
    Donzelli, M
    Chiesa, M
    Guardavaccaro, D
    Ganoth, D
    Dorrello, NV
    Hershko, A
    Pagano, M
    Draetta, GF
    [J]. NATURE, 2003, 426 (6962) : 87 - 91
  • [6] The SCF ubiquitin ligase: Insights into a molecular machine
    Cardozo, T
    Pagano, M
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2004, 5 (09) : 739 - 751
  • [7] The spindle checkpoint requires cyclin-dependent kinase activity
    D'Angiolella, V
    Mari, C
    Nocera, D
    Rametti, L
    Grieco, D
    [J]. GENES & DEVELOPMENT, 2003, 17 (20) : 2520 - 2525
  • [8] Desai A, 1999, METHOD CELL BIOL, V61, P385
  • [9] SRC HOMOLOGY-2 DOMAIN AS A SPECIFICITY DETERMINANT IN THE C-ABL-MEDIATED TYROSINE PHOSPHORYLATION OF THE RNA-POLYMERASE-II CARBOXYL-TERMINAL REPEATED DOMAIN
    DUYSTER, J
    BASKARAN, R
    WANG, JYJ
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (05) : 1555 - 1559
  • [10] A complex of Cdc4p, Skp1p, and Cdc53p/cullin catalyzes ubiquitination of the phosphorylated CDK inhibitor Sic1p
    Feldman, RMR
    Correll, CC
    Kaplan, KB
    Deshaies, RJ
    [J]. CELL, 1997, 91 (02) : 221 - 230